Navigation Links
Atrium Innovations Announces Management Changes
Date:9/10/2007

nized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees. Additional information about Atrium is available on its Web site at http://www.atrium-innov.com.

Cautionary Note and Forward-Looking Statements

This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE ATRIUM INNOVATIONS INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pilot fund brings capital to Eau Claire area innovations
2. Wisconsin state agencies commended for digital innovations
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle announces $80M renewable energy strategy
8. GE announces first installation of Discovery VCT
9. UWM announces winners of RGI awards
10. Third Wave announces two senior management appointments
11. Mirus announces new method for making antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... research executives, scientists, policy makers, and funders today convened ... at the inaugural Partnering for Cures meeting. ... the Milken Institute, convened Partnering for Cures ... discovery into an accessible therapy. This effort unites ...
(Date:12/2/2009)... , - "Bolstering Biodiversity ... Coinciding with the International Year ... hosting an international conference in Libreville,(Gabon) on the ... will be attended by government and state leaders, ...
(Date:12/2/2009)... today announced data presentations on its novel oral JAK2 ... Annual Meeting and Exposition in New Orleans. ,, Data ... Phase 1 dose-escalation trial of SB1518 detailing its safety, ... from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)... is going through,extraordinary times; markets are in turmoil and ... out that the pharma industry has been,relatively immune to ... During the midst of the ... inaugurated an R&D center in Shanghai, the largest of,its ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... linked to doxorubicin. The decision to enter the ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... the extracellular matrix, today announced it has ... human hyaluronidase enzyme,(rHuPH20) co-formulations with Humulin(R) R ... lispro) in Type 1 diabetic,patients. This study ...
... Deploys Clustered Storage to Help Redefine the ... Economics of Large-Scale Sequencing, SEATTLE, ... storage, today announced that Complete,Genomics, the world,s first provider of ... of Isilon IQ clustered,storage to unify its vast stores of ...
Other Biology Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 2Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 3
(Date:12/3/2009)... of this message: , , Preliminary Press ... California Academy of Sciences museum, Attention PIOs: Sending ... registration deadline 10 December, News Media registration ... THIS MONDAY, 7 December, Who,s coming, , ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
(Date:12/3/2009)... of the upcoming forest deal at Copenhagen in order to ... University of Leeds. , Writing today in Nature ... the carbon credit payments to be agreed at Copenhagen, known ... made to forest dwellers directly, and their property rights assured. ...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 1Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 3Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 4Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 5Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 6Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 7Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 8Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 9Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 10Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 11Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 12Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 13Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 14Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 15ProAssurance Reports Second Quarter 2009 Results 53542 1ProAssurance Reports Second Quarter 2009 Results 53542 2ProAssurance Reports Second Quarter 2009 Results 53542 3ProAssurance Reports Second Quarter 2009 Results 53542 4ProAssurance Reports Second Quarter 2009 Results 53542 5ProAssurance Reports Second Quarter 2009 Results 53542 6ProAssurance Reports Second Quarter 2009 Results 53542 7ProAssurance Reports Second Quarter 2009 Results 53542 8ProAssurance Reports Second Quarter 2009 Results 53542 9ProAssurance Reports Second Quarter 2009 Results 53542 10ProAssurance Reports Second Quarter 2009 Results 53542 11ProAssurance Reports Second Quarter 2009 Results 53542 12ProAssurance Reports Second Quarter 2009 Results 53542 13
... by the University of Colorado at Boulder reveals that ... source of fine, organic particle pollutants that contribute to ... Angeles region. , According to the study, a much ... is directly emitted by vehicles and industrial processes. Instead, ...
... 24, 2008) Self-guided treatment for depression could ... , Scientists with the National Space Biomedical Research ... that will assist astronauts in recognizing and effectively ... pose a substantial threat to crew safety and ...
... release is available in German . , ... and molluscs more than plants. This is the finding of ... Research (UFZ), TU Berlin, the German Federal Institute of Hydrology ... of observations before and after the Elbe floods of August ...
Other Biology News:CU-Boulder study suggests air quality regulations miss key pollutants 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3Vegetation hardly affected by extreme flood events 2
... Instech Solomon's laboratory animal infusion kits reduce ... an infusion study while providing sterile equipment ... kit includes everything you need for one ... Tubing and tethers will be cut to ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... an exciting new chapter to ... leadership, Agilents 7890A GC gives ... take your lab to the ... GC/MS performance, including advanced separation ...
... six short years since publication of the ... widely acclaimed Protein Protocols Handbook, there have ... biochemistry. In recognition of the level of ... evolution of new methodologies directed to study ...
Biology Products: